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Naturally occurring mutations of G protein-coupled receptors
(GPCRs) causing misfolding and failure to trafﬁc to the cell surface
can result in disease states. Some small-molecule orthosteric
ligands can rescue such misfolded receptors, presumably by facil-
itating their correct folding and shuttling to the plasmamembrane.
Here we show that a cell-permeant, allosterically binding small-
molecule agonist (Org 42599) rescues the folding and cell surface
expression, and therefore target cell signaling, of mutant human
luteinizing hormone (LH) receptors (A593P and S616Y) that cause
Leydig cell hypoplasia inman. Bothmutant receptorswere retained
in the cytoplasm whereas WT receptor localized at the cell mem-
brane, and binding of LH to cells expressing the mutant receptors
was markedly lower than to those expressing the WT receptor.
Incubation with Org 42599 increased mutant receptor expression,
cell surface localization, and the proportion of mutant receptor in
themature glycosylated form. Importantly, although LH stimulated
little (S616Y) or no (A593P) activation of cells expressing mutant
receptors, incubation of cells with Org 42599 facilitated rescue of
expression and stimulation by the native ligand, LH. Although Org
42599 could activate these receptors, it could not displace 125I-la-
beled human LH binding to the WT receptor, indicating that it acts
in an allosteric manner. Here we demonstrate a small-molecule
GPCR allosteric agonist that functionally rescues intracellularly
retained mutant LH receptors by facilitating their cell surface ex-
pression. This approach may have application for treatment of in-
fertile patients bearing suchmutations and,more broadly, for other
misfolded GPCR mutants resulting in human pathologic processes.
pharmacological chaperone | receptor trafﬁcking | infertility
Mutations in G protein-coupled receptors (GPCRs) havebeen identiﬁed for almost all endocrine hormone-signaling
deﬁciencies. The luteinizing hormone (LH) receptor is a GPCR
with a crucial role in reproduction. LH is secreted from the pi-
tuitary gland and is required for the induction of ovulation in
females and for sex steroid hormone production in bothmales and
females. Mutations in LH receptors can therefore lead to a spec-
trum of reproductive dysfunctions, with inactivating mutations
leading to decreased sex steroid hormone production and/or
problems with genitalia development (1–8).
Loss of function of mutant receptors can be a result of impaired
ligand binding or coupling to intracellular signaling pathways, but
most often are a result of poor cell surface expression of the
receptors (9). The endoplasmic reticulum (ER) contains mole-
cules involved in facilitating folding and transport of newly syn-
thesized proteins, or in the recognition of misfolded proteins that
are then targeted for degradation (10, 11). Many GPCRs have
mutations that cause retention in the ER, resulting in disease
states. Examples include mutations in the V2 vasopressin receptor
that cause nephrogenic diabetes insipidus (12), mutations in
rhodopsin that cause autosomal-dominant retinitis pigmentosa
(13), and mutations in the gonadotropin releasing hormone re-
ceptor that cause hypogonadotropic hypogonadism (14, 15).
Some small-molecule orthosteric ligands (i.e., pharmacological
chaperones) can interact with intracellularly retained receptors to
aid their folding and transport to the plasmamembrane. Examples
include antagonists able to rescue cell surface expression ofmutant
V2 vasopressin receptors (16), agonists and antagonists able to
rescue mutant δ-opioid receptors (17), and an antagonist able to
rescue mutant gonadotropin releasing hormone receptors (14).
Such compounds therefore have important therapeutic potential.
In contrast to these orthosteric ligands, a group of thienopyr-
imidine compounds have recently been identiﬁed that allosteri-
cally activate the LH receptor (18). The present study dem-
onstrates that one such thienopyrimidine, Org 42599 (Fig. S1),
rescues plasmamembrane expression and thereby signaling of two
intracellularly retained mutant LH receptors (A593P and S616Y)
identiﬁed in human patients with impaired reproductive function
(for details of patient phenotypes, see SI Text). This compound
has potential for use in the treatment of infertile patients bearing
such LH receptor mutations and provides a unique therapeutic
paradigm to use allosterically binding small-molecule agonists
to target other misfolded GPCRs. The allosteric nature of the
compound increases its therapeutic potential because, unlike pre-
viously described pharmacological chaperones, it does not com-
pete with native ligands, thereby allowing activation of rescued
mutant receptors by endogenous ligands.
Results
Mutant LH Receptors Are Retained Intracellularly. Cellular localiza-
tion of myc-tagged WT and mutant LH receptors was determined
by confocal microscopy by using an anti-myc antibody (green) and
DAPI nuclear marker (blue). In the absence of ligand, the WT
receptor was expressed at high levels and was predominantly lo-
cated at the cell surface. However, both mutant receptors were
expressed at much lower levels and were predominantly located
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intracellularly (Fig. 1, Left). This was supported by cell surface
radioligand binding assays in whichmaximal speciﬁc binding of the
cell impermeable native ligand, 125I-labeled human LH (hLH),
was signiﬁcantly lower for cells expressing theA593P (18%ofWT)
and S616Y (33% of WT) mutant receptors (Fig. S2).
The decrease in binding to cells expressing the S616Y mutant
receptor is a result of poor cell surface receptor expression and
not reduced afﬁnity for the ligand, as the afﬁnity of cell surface
LH binding to cells expressing WT and S616Y mutant receptors
was not signiﬁcantly different (Fig. S2). Binding of the radio-
ligand to A593P mutant receptors at the cell surface was too low
for determination of binding afﬁnity. However, binding afﬁnity
could be determined on intracellular A593P mutant receptors
and was not different to that seen for the WT receptor (Fig. S3).
Cells Expressing Mutant LH Receptors Are Poorly Activated by LH.
Stimulation of cAMP accumulation after activation of the re-
ceptors with LH was measured by two different methods. The ﬁrst
directly measured cAMP levels in cell lysates by ELISA after 1 h
of ligand stimulation and the second measured the downstream
activation of a luciferase reporter gene under the control of
a cAMP response element (CRE) after 24 h stimulation with li-
gand. LH activated theWT receptor with high potency [EC50, 0.15
nM (cAMP ELISA) or 0.02 nM (CRE-luciferase)]. However, in
cells expressing the mutant receptors, LH induced little (S616Y)
or no (A593P) stimulation (Fig. 2 and Table S1).
Org 42599 Acts as an Allosteric Agonist at the LH Receptor. Org
42599 (Fig. S1 shows compound structure) is a triﬂuoroacetic acid
salt form of the thienopyrimidine Org 43553, an allosteric LH
receptor agonist shown to induce ovulation in vivo (19, 20). Even
at millimolar concentrations, Org 42599 was unable to displace
binding of 125I-hLH to WT receptors (Fig. S2). However, it was
able to stimulate this receptor, albeit with lower potency than LH
(Fig. 3 and Table S1), conﬁrming that it binds to an allosteric site.
Incubation with Org 42599 Rescues Cells Surface Expression of A593P
and S616Y Mutant LH Receptors. To determine whether Org 42599
can act as a pharmacological chaperone and rescue the cell surface
expression of the mutant receptors, its effects on cellular locali-
zation of the mutant receptors were initially examined by confocal
microscopy. In contrast to the predominantly intracellular locali-
zation of the mutant receptors seen in the absence of Org 42599,
cells incubated with the compound displayed strong cell surface
receptor expression (Fig. 1, Right). This effect was most pro-
nounced with cells expressing the S616Y mutant receptor. In
addition to alterations in cellular localization of the mutant re-
ceptors, incubation with Org 42599 appeared to increase the
number of cells expressing the receptor and the level of receptor in
these cells. Examination of receptor protein expression byWestern
immunoblottting also demonstrated that incubation with Org
42599 not only increased the proportion of mutant receptors
present in a mature (i.e., glycosylated) form, but also increased
overall expression levels of the mutant receptors (Fig. S4), sug-
gesting that Org 42599 stabilizes the folding of the mutant recep-
tors and decreases targeting to degradation pathways.
Preincubation of cells expressing mutant receptors with Org
42599 increased cell surface 125I-hLH binding proportionally to
the duration and concentration of Org 42599, with maximal
increases seen after 24 h with 1 to 10 μM Org 42599 (Fig. 4). In
contrast, there was no increase in binding to cells expressing the
WT receptor after Org 42599 incubation. Subsequent studies on
rescue of mutant receptor expression were therefore carried out
after incubation of cells with 1 μM Org 42599 for 24 h, unless
mentioned otherwise.
The effect of Org 42599 incubation on myc-tagged receptor
cellular localization was also measured by ﬂuorescent antibody
imaging of intact and permeabilized cells (21). Cells were in-
cubated with a range of concentrations of Org 42599 for 24 h,
Fig. 1. Cellular localizations of mutant LH receptors are altered after in-
cubation with Org 42599. Cells expressing WT, A593P mutant, or S616Y
mutant LH receptors were incubated in the presence of vehicle (Left) or 1 μM
Org 42599 (Right) for 24 h before ﬁxation, ﬂuorescent labeling, and confocal
imaging (Materials and Methods). LH receptors (myc tagged) are labeled in
green and cell nuclei marker (DAPI) in blue. Images are from one experiment
and are representative of three independent experiments with similar re-
sults. (Scale bar: 10 μm.)
Fig. 2. LH elicits little or no activation of cells expressing mutant LH receptors. Measurement of cAMP accumulation by cAMP ELISA after 1 h stimulation (A)
or CRE-luciferase reporter gene activation after 24 h stimulation (B) in cells expressing WT (●), A593P mutant (▪), or S616Y (▲) mutant LH receptors over
a range of concentrations of LH (Materials and Methods). Data were ﬁtted by sigmoidal dose–response curves with Hill coefﬁcients of unity. Data are
presented as fold versus basal values for each receptor and are mean ± SEM from at least three independent experiments.











which resulted in large increases in cell surface receptor expres-
sion (intact cells) of the mutant receptors in a concentration-
dependent manner (Fig. S5).
To determine whether the rescue of cell surface expression
was a persistent or transient effect, cells were incubated with Org
42599 and the binding of 125I-hLH measured directly, or after
extensive washing out of the ligand for 18 h (which is necessary
to remove all intracellular Org 42599). The increased binding
of 125I-hLH to cells expressing the mutant receptors after pre-
incubation with Org 42599 was abolished after 18 h of washing,
indicating that the rescue is transient (Fig. S6).
Incubation with Org 42599 Rescues Signaling in Cells Expressing
Mutant LH Receptors. In contrast to LH, which stimulated little or
no activation of cells expressing the mutant receptors in the CRE-
luciferase reporter gene assay (Fig. 2B and Table S1), a large
response to Org 42599 stimulation was observed (Fig. 3 and Table
S1). This is presumably a result of concomitant receptor rescue
and stimulation, as these experiments were conducted over a time
frame of 24 h. Interestingly, the A593P mutant was less sensitive
to stimulation by Org 42599 but revealed a greater efﬁcacy. This
may be a result of the dynamics of conformational instability and
desensitization with the prolonged incubation necessary for res-
cue studies, which was not investigated further here.
To determine whether Org 42599 restored LH-stimulated sig-
naling in cells expressing mutant receptors, cells expressing the
S616Y mutant receptor were stimulated with LH after pre-
incubation in the presence or absence of Org 42599. Cells were
preincubated with a lower concentration ofOrg 42599 (0.1 μM) for
shorter incubation times (2, 3, and 6 h) than used in the previous
experiments to ensure that any cAMP accumulation induced by
Org 42599 would be minimal, thus enabling the effects on the LH
response to be determined more easily. In each case, a marked
increase in cAMPresponse toLH in cells expressing themutantLH
receptor was seen for cells preincubated with Org 42599 (Fig. 5).
Discussion
The majority of loss-of-function GPCR mutations causing disease
states are caused by misfolding and retention of the receptor in the
ER and the subsequent lack of receptor at the cell membrane—its
functional location. Cell-permeant orthosteric ligands that act as
pharmacological chaperones can bind nascent receptor in the ER
and rescue cell surface expression of these mutant receptors, and
therefore have therapeutic potential (22). We now demonstrate
that an allosteric LH receptor agonist is able to functionally rescue
surface localization and also stimulate signaling of cells expressing
two mutant LH receptors (A593P and S616Y) identiﬁed in
patients with impaired reproductive function (1, 23). Rescue of
surface expression with the allosteric agonist also increased sig-
naling by the orthosteric endogenous ligand, LH.
Studies of 125I-hLH binding with confocal microscopy visualiza-
tion and Western immunoblotting of LH receptors demonstrated
that A593P and S616Y mutant LH receptors are retained intra-
cellularly inan immature formwithin theER, inagreementwithour
previous study (24). As demonstrated herein and in the previous
report (24), the decreased cell surface expression is more profound
for A593P compared with S616Y. Moreover, the degree of intra-
cellular retention and resulting decreased cell surface expression of
the mutants correlates with the severity of the observed clinical
phenotypes in the patients with these two LH receptor mutations
(SI Text provides details of patient phenotypes) (1, 23, 25).
Although cell surface expression was impaired, neither receptor
mutation affected the ability of LH to bind to the receptor as
demonstrated in binding studies on cell surface and intracellular
receptors (Figs. S2 and S3). This is not unexpected, as LH binding
is located exclusively in the large N-terminal region of the rece-
ptor, and these mutations are both within the transmembrane do-
mains. Although the mutant receptors have normal and high
afﬁnity for LH, cells expressing the mutants exhibited little
(S616Y) or no (A593P) LH-stimulated cAMP response. This is
a result of the decreased cell surface expression of the mutant
receptors, thus leading to reduced agonist potency and maximal
responses as described by the operational model of pharmaco-
Fig. 4. Binding of 125I-hLH to cell-surface mutant LH receptors is increased in a time- and concentration- dependent manner after incubation with Org 42599.
Binding of 125I-hLH to cells expressing WT, A593P mutant, or S616Y mutant LH receptors was measured after incubation with Org 42599 (1 μM) for a range of
incubation times (A) or for 24 h with a range of concentrations of Org 42599 (B). After incubation with Org 42599, cells were washed once for 1 h with
Complete media before incubation with radioligand. Data are presented as fold versus binding in the absence of Org 42599 treatment and are mean ± SEM
from at least three independent experiments. Note WT receptor binding is not increased by Org 42599 treatment (1.0-fold vs. vehicle control), whereas
mutant receptors show a time- and concentration- dependent increase in binding after incubation with Org 42599. *P < 0.05 and **P < 0.01 (one-sample t
test) for comparison with no change compared with vehicle control (1.0-fold change, dotted line).
Fig. 3. Org 42599 elicits robust activation of cells expressing WT and mu-
tant LH receptors. Measurement of cAMP accumulation by CRE-luciferase
reporter gene activation after 24 h stimulation in cells expressing WT (●),
A593P mutant (▪), or S616Y (▲) mutant LH receptors was determined over
a range of concentrations of Org 42599 (Materials and Methods). Data were
ﬁtted by sigmoidal dose–response curves with Hill coefﬁcients of unity. Data
are presented as fold versus basal values for each receptor and are mean ±
SEM from at least three independent experiments.
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logical agonism (26).DecreasingWTLH receptor expression gives
a similar decrease in potency and maximal stimulation of LH (27).
Incubation of cells expressing A593P and S616Y mutant recep-
tors with Org 42599 increased the total level of mutant receptor
expression, the proportion of mutant receptors in a mature form,
and their cell surface expression. These data therefore suggest that
Org 42599 facilitates the folding and transport of misfolded re-
ceptor retained within the ER, thereby increasing the trafﬁcking of
receptor protein to the cell surface and/or reducing the amount of
receptor targeted to the proteasome. These mutant LH receptors
have been shown to associate with different intracellular proteins
compared with the WT LH receptor (24). Unlike the WT LH
receptor, the mutant receptors interact with 94-kDa glucose-
regulated protein (Grp94) and/or binding Ig protein, which are
stress proteins that can aid protein folding and translocation within
the ER but also have a role in transporting misfolded proteins to
the proteasome. In addition, unlike the WT receptor, the A593P
mutant receptor does not interact with protein disulphide isom-
erase, an enzyme involved in protein folding in the ER through
catalysis of disulﬁde bonds (24). Thus, Org 42599 is presumably
increasing association with some, and decreasing associations with
other, intracellular proteins by binding to the receptors’ allosteric
sites to stabilize their folding within the ER. Further studies on the
association of intracellularly retained mutant LH receptors with
intracellular proteins in the absence and presence of Org 42599
should shed more light on these interactions.
In the CRE-luciferase reporter gene assay, Org 42599 was able
to robustly activate cells expressing the mutant receptors whereas
LH (without previous Org 42599 treatment) elicited little
(S616Y) or no (A593P) response (Table S1). The CRE-luciferase
reporter gene assay measures receptor activation after 24 h ligand
incubation and therefore presumably allows for increased mutant
receptor cell surface expression and concomitant or subsequent
activation by Org 42599. Interestingly, the increased respon-
siveness to Org 42599 in the CRE-luciferase assay, after a long
ligand incubation time (24 h), was not restricted to the mutant
receptors. At theWTLH receptor, Org 42599 behaved as a partial
agonist (achieving approximately 25% of the maximal response to
LH) in the cAMP ELISA that entailed a 1 h incubation with li-
gand, but almost a full agonist in the CRE-luciferase reporter
gene assay (Table S1). This may be a result of signal ampliﬁcation
in the CRE-luciferase assay and intrinsic limitations of the system
or cells used preventing any further cAMP accumulation after
activation with LH. The rescued functionality of the mutant
receptors was further demonstrated by the increased response
to LH, measured in cells expressing these receptors, after pre-
incubation with Org 42599 (Fig. 5).
Our ﬁndings suggest that Org 42599, or similar compounds, may
be useful for treatment of infertile patients expressing these mu-
tant receptors, and for whom there are currently no therapeutic
options. Previous studies examining rat LH receptor mutants that
are similarly misfolded and retained intracellularly demonstrated
that incubations of cells at decreased temperatures rescued the
mutants by increasing their cell surface expression (28). In agree-
ment with the ﬁndings herein, it was observed that mutants with
some degree of cell surface expression exhibited a greater ability to
be rescued than those that were more profoundly retained (pre-
sumably as a result of to more extensive misfolding). Although
treatment with decreased temperature as a means to rescue mis-
folded LH receptor mutants provided a proof of principle re-
garding the potential restoration of target cell responsiveness by
facilitating the folding and cell surface expression of otherwise
intracellularly retained immature receptor, this method is obvi-
ously impractical from a therapeutic perspective. In contrast, it is
entirely feasible that treatment with an allosteric agonist such as
Org 42599 may be therapeutically relevant. It has previously been
demonstrated that the closely related compound Org 43553 is
orally active and able to induce ovulation in normal rodents (19),
demonstrating the in vivo activity of this class of compounds and
further supporting their clinical potential.
Both mutant receptors investigated in this study were rescued
to a lesser or larger extent by Org 42599. However, it is not clear
whether this would be the case for all ER-retained mutant human
LH receptors. GPCRs represent 80% of all membrane receptors
in man, and ER retention of GPCRs causes a wide range of dis-
ease states, so the use of pharmacological chaperones has vast
therapeutic potential. As the compound described herein acts as
an allosteric agonist, unlike previously described pharmacological
chaperones, it has functions in rescuing cell surface expression,
activating the mutant receptors, and allowing increased activation
of the receptors with endogenous ligands. It thus has the capacity
to facilitate responses to both Org 42599 and endogenous LH in
vivo. Furthermore, mutations of GPCRs, including the LH re-
ceptor (6, 8, 29), have been identiﬁed in regions of the receptor
that compromise binding of their cognate ligands. Therefore,
there is potential for cell-permeant allosteric agonists such as the
molecule described here to rescue the function of receptors with
mutations affecting ligand binding.
In summary, this study identiﬁes a low-molecular-weight allo-
steric agonist able to rescue cell surface expression, and therefore
signaling, of two intracellularly retained, naturally occurring,
mutant human LH receptors. This opens up the possibility of
using such compounds for the therapeutic treatment of infertile
patients with LH receptor mutations that cause intracellular re-
tention of the misfolded receptors. Importantly, it provides a
proof of concept for broader application in subjects with other
mutant GPCRs.
Materials and Methods
Materials. Recombinant LH (lutropin alfa; Luveris) was obtained from Serono.
Org 42599 was provided by Merck Sharp and Dohme. 125I-hLH was iodinated
in house by using hLH obtained from the National Hormone and Peptide
Program, National Institute of Diabetes and Digestive and Kidney Diseases,
and A. F. Parlow (National Hormone and Peptide Program, Torrance, CA).
Cell Culture. HEK 293 cells stably expressing WT or mutant human LH
receptors with N-terminal myc tags were maintained in Complete media
[DMEM, 10% FCS, 4 mM L-glutamine, penicillin (100 U/mL)/streptomycin (100
μg/mL)] supplemented with 500 μg/mL G418 when appropriate, at 37 °C in
a humidiﬁed 5% CO2 atmosphere. All cell culture plates and dishes were
treated with Matrigel (BD Biosciences) before cell seeding unless mentioned
otherwise. Cell culture reagents were obtained from Invitrogen or PAA
Laboratories.
Fig. 5. LH stimulation of cells expressing S616Y mutant LH receptors is in-
creased by preincubation with Org 42599. cAMP accumulation was mea-
sured by cAMP ELISA after stimulation of cells expressing S616Y mutant LH
receptors with LH (3 nM) for 1 h at 37 °C after preincubation in the presence
or absence of Org 42599 (0.1 μM) for 2 to 6 h and washing once for 1 h
(SI Materials and Methods). Data are mean ± SEM from three independent
experiments and are presented as percentage of the maximum LH response
obtained in the absence of Org 42599 incubation.











Confocal Microscopy. Cells, seeded in black poly-D-lysine–coated, glass-
bottomed plates, were incubated with Org 42599 (1 μM) or appropriate
vehicle in Complete media for 24 h at 37 °C. Cells were then washed with PBS
solution and ﬁxed/permeabilized by incubation with methanol for 10 min at
−20 °C. Cells were then washed three times with PBS solution (10 min each
wash), followed by addition of blocking solution [PBS solution containing
20% normal goat serum (Biosera) and 2.5% BSA], and incubated for 1 h at
room temperature. Following blocking, cells were incubated with primary
antibody (mouse anti–c-myc clone 9E10; 1:50–1:100; Santa Cruz) overnight at
4 °C followed by three washes with PBS solution (10 min each wash), then
incubated with secondary antibody (Alexa Fluor 488-conjugated goat anti-
mouse; 1:200; Invitrogen) for 1 h at room temperature and washed three
times with PBS solution (10 min each wash). Cells were then counterstained
with DAPI (1:100; Sigma) for 5min at room temperature beforewashing twice
with PBS solution (5min eachwash). Finally, cells were visualized using an LSM
710 confocal microscope with a 40× water-corrected objective (Zeiss).
cAMP Accumulation Assays. cAMP ELISA. Cells were incubated in the presence
or absence of a range of concentrations of ligand (3 pM to 3 nM LH or 1 nM to
10 μMOrg 42599; LH concentrations calculated assuming a molecular weight
of 28 kDa) in cAMP buffer (Hepes–DMEM supplemented with 0.1% BSA and
1 mM 3-isobutyl-1-methylxanthine) for 1 h at 37 °C. Cells were then lysed by
incubation for 20 min with HCl (0.1 M). Cell debris was removed by centri-
fugation at 600 × g for 10 min, and the level of cAMP in the supernatants
was determined using a direct cAMP enzyme immunoassay kit (Enzo Life
Sciences). To determine activation of rescued receptors by LH, cells were
preincubated with Org 42599 (0.1 μM) in Complete media for 2 to 6 h and
were then washed with Complete media for 1 h at 37 °C before incubation
with LH (3 nM) in cAMP buffer for 1 h at 37 °C. Cells were lysed and cAMP
levels measured as described earlier.
CRE-luciferase reporter gene assay. Cells were transiently transfected with
Renilla luciferase (33 ng per well; Promega) and CRE-luciferase (467 ng per
well; Clontech) DNAusing FuGENE 6 transfection reagent (Roche). At 24 h after
transfection, cells were cells washed twicewith PBS solution before addition of
serum-free media [DMEM, penicillin (100 U/mL)/streptomycin (100 μg/mL),
4mM L-glutamine, 10mMHepes] and further incubation for 24 h at 37 °C. Cells
were then incubatedwith a rangeof concentrations of ligand (3 pM to 3 nMLH
or 1 nM to 10 μM Org 42599; LH concentrations calculated assuming a mo-
lecular weight of 28 kDa) in serum-free media for 24 h at 37 °C. Cells were
washed twice with PBS solution before lysis and measurement of luciferase
activity using aDual-Luciferase Reporter Assay System (Promega) and FLUOstar
OPTIMA microplate reader (BMG Labtech). CRE-luciferase activity was nor-
malized using the Renilla luciferase activity measurements for each well.
Data were calculated as fold versus basal for each receptor. Where ap-
propriate, data were analyzed by nonlinear regression using GraphPad Prism
software (GraphPad) and were ﬁtted to sigmoidal dose–response equations
to generate values for EC50 and maximal stimulation.
Radioligand Cell Surface Binding Assays. Time and concentration dependence of
receptor rescue. Cells were incubated for 1.5 to 36 h at 37 °C in the presence or
absence of Org 42599 (1 μM) in Complete media (for time dependence assay)
or in the presence or absence of a range of concentrations of Org 42599 (10
μM to 1 nM) in Complete media for 24 h at 37 °C (for concentration de-
pendence assay). Cells were thenwashedwith Completemedia for 1 h at 37 °C
before addition of 125I-hLH (100,000 cpm), prepared in binding buffer (Hepes–
DMEM supplemented with 0.1% BSA), and incubated for 4 h at 4 °C. Cells
were lysed by incubation for 15minwith NaOH (0.1M), and their radioactivity
was measured using a Wizard 1470 automatic γ-counter (Perkin-Elmer).
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